Index by Company
- Abbott and Idun to Develop Apoptotic Cancer Drugs, Jan 12 Press Release
- Abbott Laboratories Announces European Approval of Uprima
- Æterna: Phase I/II study results in prostate cancer confirm Neovastat's...
- Warner-Lambert to Aquire Agouron, Jan 26 99
- Agouron Phase I Results April 17, 1998
- Alza Announces Approval of Viadur For Once-Yearly Palliative Treatment
Of Advanced Prostate Cancer - Amgem and Praecis Phase III Trial Results Announced...
- Aronex Study of ATRAGEN Jan 1999
- Aronex Pharmaceuticals Starts Clinical Trial of Atragen for Prostate Cancer
- Bostwick Laboratories Announces uPM3(TM) Test, First Genetic Test for
Prostate Cancer (Sept 23,2003) - Cell Pathways Scientists Describes Mechanism...
- Cell Pathways Says FDA Won't Approve Aptosyn for FAP at This Time
- CytoTherapeutics announces human brain stems purified from human tissue.
- Endocare Announces Medicare Coverage for its Cryosurgery Procedure for
Prostate Cancer: Feb 16 1999 - Bristol Myers-Squibb and EntreMed Modify Research Agreement : Feb 10 1999
- Entremed, Inc. Signs Letter of Intent for GMP Production of Angiostatin Protein
- Etremed Signs Agreement with NCI to Study 2- Methoxyestradiol
- Entremed Scientists Report Potent Angiogenic Effects in Preclinical Trials
- EntreMed Low-Dose Cancer Therapy Featured at AACR Meeting
- Genzyme gets $5 Million for p53 Gene Therapy European Patent February 5 1999
- Genzyme Licences Angiogenesis Inhibitor from Folkman Lab February 9 1999
- Genzyme and ATIII LLC Agree to Develop aaATIII as a Potential Cancer Therapy
- Preclinical Study Cites Potency of aaATIII Discovered by Folkman, O'Reilly
- NEW ANTI-ANGIOGENIC PROTEINS DISCOVERED
- Immunexs TRAIL Molecule Shows Potential as Anti-Tumor Agent
- IMPATH Announces Venture with Physicians Network, Jan 15
- Medarex MDX-210 in Trials for Prostate Cancer, press release December 3 1998
- Mitotix Acquires License to p27 Gene, June 1996
- Entremed Scientists Report Potent Angiogenic Effects in Preclinical Trials
- New Ãpoque Of Cancer Treatment
Options To Impact Competitive Situation In Cancer
Pharmaceutical Therapeutics Market - Novartis submits NDA for Zometa® (zoledronic acid for injection)
- Nycomed Amersham Imaging launches Website
- Progenics and Cytogen Vaccine...at CaP CURE Retreat
- Roberts Pharmaceutical LHRH One Year Implant Nearly Ready February 9 1999
- SafeScience Accelerates Clinicals Studies of GBC-590 in Prostate and Pancreatic
Cancer Patients (June 1999) - TAP Pharmaceutical Products Inc. and Seven Others Charged With Health Care
Crimes; Company Agrees To Pay $875 Million To Settle Charges,
Reports U.S. Attorney. October 2001
